Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 17;9(11):ofac544. doi: 10.1093/ofid/ofac544

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published by Oxford University Press on behalf of Infectious Diseases Society of America 2022.

This work is written by (a) US Government employee(s) and is in the public domain in the US.

PMC Copyright notice

Figure 1. — Dynamics of immunologic and virologic parameters in study participants before and 10–14 days after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) booster vaccination. (A) Study schema. (B) Comparison of antibody titers against SARS-CoV-2 nucleocapsid protein, receptor-binding domain (RBD), S1 subunit, and Spike protein. (C) Levels of total human immunodeficiency virus (HIV) In this deoxyribonucleic acid (DNA), intact HIV proviral DNA, and cell-associated HIV ribonucleic acid (RNA) before and after SARS-CoV-2 booster vaccination. (D) Frequencies of TIGIT, PD-1, CD226, and CD38HLA-DR on CD8⁺ T cells before and after SARS-CoV-2 booster vaccination. (E) Effect of the SARS-CoV-2 booster vaccination on the frequency of IFN-γ⁺TNF-α⁺MIP-1β⁺ HIV Gag-specific CD8⁺ T cells in study participants. (F) Frequencies of spike-specific CD4⁺ and CD8⁺ T cells (left panel) and spike-specific CD4⁺ cTfh cells (right panel) before and after SARS-CoV-2 booster vaccination.